In recent years, rapid advances in our understanding of human biology at the molecular and genetic levels have paved the way for a potential "golden age" of cancer treatment. Distinctive characteristics of each tumor have triggered developments for personalised treatments that are target specific to cancer cells and also in retraining the body's immune system. A recent market survey reported that oncology spending is expected to reach around 208 billion U.S. dollars worldwide and rise to over 300 billion dollars by 2026, with a maximum projection of 12 percent CAGR between the years. There has been extensive competition in the oncology therapeutic area, with immuno-oncology therapy being the top mechanism of action (pharmacology) of drugs in the R&D pipeline worldwide. As of 2022, nearly 3300 active compounds constituted the immuno-oncology therapy. Statistics reveal that the European interventional oncology device market will significantly rise to 1171.2 million U.S dollars in the year 2025, compared to 636.6 million U.S dollars in 2018. At this juncture, a wide variety of Oncology solutions providers are entering the market with advanced and integrated technologies. This edition of Healthcare Tech Outlook Europe highlights the key developments in the space and how companies are leveraging healthcare tech to mitigate challenges involved in oncology.
This edition features thought leadership articles from BretSchipper, Chief of Surgical Oncology and Director of Oncologic Surgery at Hartford Hospital, Matt Manning, MD, FASTRO, Chief of Oncology at Cone Health, TouficKachaamy, Medical Director of Cancer Treatment Centers of America. Additionally, the edition features innovative solutions from companies, including OncoGenomX and C-RAD to help readers navigate the best-of-breed system and solution providers.
